Compare APPN & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPN | TYRA |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2017 | 2021 |
| Metric | APPN | TYRA |
|---|---|---|
| Price | $21.87 | $31.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $29.80 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 1.0M | 966.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,743,000.00 | N/A |
| Revenue This Year | $13.79 | N/A |
| Revenue Next Year | $10.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.29 | N/A |
| 52 Week Low | $18.63 | $9.96 |
| 52 Week High | $46.06 | $40.65 |
| Indicator | APPN | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 55.10 |
| Support Level | $19.44 | $24.77 |
| Resistance Level | $22.33 | $31.57 |
| Average True Range (ATR) | 1.33 | 1.88 |
| MACD | -0.31 | 0.67 |
| Stochastic Oscillator | 40.24 | 86.18 |
Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations, and also has its presence Internationally.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.